Description

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (XinBiTai) deliver a fixed?dose combination of nucleoside and nucleotide analogs—emtricitabine 200?mg and tenofovir disoproxil fumarate 300?mg per tablet. These agents inhibit HIV?1 reverse transcriptase and viral DNA polymerase, effectively disrupting viral replication. Widely used in pre?exposure prophylaxis (PrEP) and combination antiretroviral therapy. Manufactured under approval H20223386 in China, each tablet ensures precise dosing and consistent bioactivity. Packaged in 30?count units. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (XinBiTai) act by dual inhibition of HIV?1 reverse transcriptase and viral DNA polymerase, interrupting viral genome synthesis. In research models, these tablets are used to simulate PrEP regimens, study resistance mutation pathways, test antiviral potency, and evaluate combination therapies. This formulation is ideal for virology assays, pharmacodynamics studies, and antiviral drug screening. For laboratory or preclinical research use only.

Side Effects (For Reference Only in Models)

In experimental or preclinical models, observed effects may include gastrointestinal symptoms (nausea, diarrhea), fatigue, headache, skin pigmentation, kidney enzyme changes, or mild metabolic disturbances. Rare renal effects such as Fanconi?like features or bone density changes may appear in prolonged high-dose studies. These observations should inform dosing and safety design in experimental models.

Disclaimer

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (XinBiTai) 200?mg/300?mg are strictly intended for laboratory research use only. Not for human or veterinary therapeutic use.